- Clinical Effects of Lidex(R) Cream
-
Lee SB, Cha MG, Byun DG
- KMID: 1930980
- Korean J Dermatol.
- 1975 Dec;13(4):281-283.
Lidex' cream (Fluocinonide 0.05% in FAPG base) is a new fluorina,ted topical corticosteroid, and its clinical effect was assessed by applying topically three to four times daily to the lesions... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessment of Atrophy of Human Epidermis Caused by Various Corticosteroids Using Chamber Occlusion and Histometry
-
Chun YI, Yang JM, Suh MS, Eun HC, Lee YS
- KMID: 2231548
- Korean J Dermatol.
- 1986 Oct;24(5):579-585.
The aim of this stud y was to compare the epidermal thinning properties of four corticosteroid ointments applied under occlusion, using histology and histometry. The results were surnmerized as follows:... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical experience with Fluocinonide cream
-
Lee YB, Houh W
- KMID: 1664502
- Korean J Dermatol.
- 1975 Jun;13(2):109-112.
Lidex(Fluacinonide) 0.05% in FAPG base is a new fluorinated topical corticosteroid. 30 patients with different steroid responsive dermatoaes were treated with 0. 05% Lidex. The diagnosis included atopic dermatitis, contact... -
- CITED
-
- Close
- SHARE
-
- Close
- Therapeutic Experience with Clocortolone Pivalate
-
Chyung EJ, Lee KW, Kim CW
- KMID: 1664740
- Korean J Dermatol.
- 1977 Dec;15(4):443-446.
Puraotix-C(0.1% Clocortolone Picalats Cream) is a new di-halogenated topical corticosteroid, and used in trial for treating several kinds of dermatoses. We treated 30 patients with Purantix-C who had one of... -
- CITED
-
- Close
- SHARE
-
- Close
- A Study on the Effect of Topical Nonsteroidal Anti - inflammatory Drugs And Cortisosteroids on Ultraviolet Light - Induced Erythema
-
Kook HI, Han JY
- KMID: 1677998
- Korean J Dermatol.
- 1980 Apr;18(2):115-120.
lt is generally beIieved that several chemical mediators such as histamine, kinine, prustaglandin E and lysosomal enzyme are related to the pathogenesis of sunburn, but the exact mechenism of erythema... -
- CITED
-
- Close
- SHARE
-
- Close
